Skip to main content
Article
The use of salivary cortisol as an index of chronic stress that correlates with depression in prostate cancer patients
Psycho-Oncology
  • Christopher Sharpley, University of New England
  • David R.H. Christie, University of New England
  • Vicki Bitsika, Bond University
  • Linda L. Agnew, University of New England
  • Nicholas M. Adronicos, University of New England
  • Mary E. McMillan, University of New England
  • Timothy M. Richards, University of New England
Date of this Version
1-1-2016
Document Type
Journal Article
Publication Details

Citation only

Sharpley, C. F., Christie, D. R. H., Bitsika, V., Agnew, L. L., Andronicos, N. M., McMillan, M. E., and Richards, T. M. (2016). The use of salivary cortisol as an index of chronic stress that correlates with depression in prostate cancer patients. Psycho-Oncology, 1-9.

Access the journal

This article is protected by copyright. All rights reserved.

Abstract

Extract:

Methods: A sample of saliva was collected from 107 Prostate Cancer (PCa) patients 45 min after waking in the morning (i.e., at the apex of the diurnal variation). Patients also completed the PHQ9 9 , a brief and validated self-report scale for measuring Major Depressive Disorder, on the same day. Background data regarding cancer status and treatment were also collected. Cortisol assay procedures were commensurate with those in the current and past literature.

Results: Patients were aged between 52 and 82 years (M = 68.4yr, SD = 6.2yr), had received their diagnosis an average of 19.7 months prior (range = 2 to 83mo). Most (85.7%) lived with their wife or partner, with 8.8% divorced, 2.2% widowed and 3.3% never married. Most (70.3%) were experiencing their first bout of PCa, with 28.6% suffering from recurring PCa and 1.1% in remission. Past treatments included radiation therapy (0.9%), surgery (41.8%), hormone therapy (14.5%), combinations of these treatments (2.7%), no treatment (1.8%), and watchful waiting (38.3%). Current treatments were: radiation therapy (73.2%) awaiting surgery (0.8%), hormone therapy (0.0%), combinations of these (23.5%), no treatment (0.8%), and watchful waiting (1.7%). PHQ9 scores ranged from 10 to 23 (M = 12.6, SD = 2.6). The authors of the PHQ9 described scores of 10 to 14 as “moderate, requiring a treatment plan”, 15 -19 as “moderately severe, requiring immediate” treatment, and 20-27 as “severe”, also requiring immediate treatment.

Citation Information
Christopher Sharpley, David R.H. Christie, Vicki Bitsika, Linda L. Agnew, et al.. "The use of salivary cortisol as an index of chronic stress that correlates with depression in prostate cancer patients" Psycho-Oncology (2016) p. 1 - 9 ISSN: 1099-1611
Available at: http://works.bepress.com/vicki_bitsika/75/